Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06832982 | Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 | PHASE1 | RECRUITING | 66 | — | — | Feb 24, 2025 | Feb 19, 2028 | Apr 9, 2026 | 10 | China |
the maximum tolerated dose(MTD)
the phase II recommended dose(RP2D)
incidence and serverity of DLT
incidence and serverity of adverse events(AE)
incidence and serverity of serious adverse events(SAE)
| Arm | Type | Description |
|---|---|---|
| Single dose escalation | EXPERIMENTAL | 42patients for dose escalation ,total 6 dose group |
| Combination therapy-FS8002 and Toripalimab Injection | EXPERIMENTAL | Toripalimab Injection and FS8002 |
| Combination therapy-FS8002 and Toripalimab Injection and Chemotherapy | EXPERIMENTAL | Toripalimab Injection and FS8002 and Chemotherapy |
| Name | Type | Description |
|---|---|---|
| FS-8002 injection | DRUG | Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first |
| Toripalimab Injection | COMBINATION_PRODUCT | Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first |
| Chemotherapy | COMBINATION_PRODUCT | Administrated per the chemotherapy chosed by the investigator until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first |
Inclusion Criteria: 1. Patients with advanced solid tumors confirmed by histology or cytology who have failed or become intolerant to previous standard treatments, or who do not have a standard treatment regimen.GBM patients must be primary GBM and first recurrence after adjuvant radiochemotherapy;...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |